Overall | F.up 5 yy | F.up > 5 yy | |
---|---|---|---|
N° of patients | 367 | 60 | 307 |
Mean age (years), (median, range) | 64.8 (66, 47-77) | 64.1 (65, 49-74) | 64.9 (66, 47-77) |
Mean follow up (months), (median, range) | 89.7 (84, 60-156) | 60 | 95.5 (87, 61-156) |
Follow up time: (years) n (%) | |||
5 | 60 (16.3) | ||
6-7 | 146 (39.8) | ||
8-9 | 81 (22.1) | ||
> 10 | 80 (21.8) | ||
Pre-operative PSA (ng/ml) mean (median, range) | 14.6 (10.2, 0.8-87) | 12.8 (9, 3.9 - 63) | 15 (10.6, 0.8-87) |
Pre-operative PSA (ng/ml) | n (%) | n (%) | n (%) |
<10 | 165 (45.0) | 34 (56.6) | 131 (42.7) |
10-20 | 134 (36.5) | 17 (28.3) | 121 (39.4) |
>20 | 68 (18.5) | 9 (15.1) | 55 (17.9) |
Specimen Gleason Score | n (%) | N (%) | n (%) |
2-6 | 154 (42.0) | 31 (51.7) | 123 (40.1) |
7 | 146 (39.8) | 19 (31.7) | 127 (41.3) |
8-10 | 67 (18.2) | 10 (16.6) | 57 (18.6) |
Pathological stage (TNM 1997) | n (%) | n (%) | n (%) |
T2 | 222 (60.5) | 40 (66.7) | 182 (59.3) |
T3a | 77 (21.0) | 13 (21.6) | 64 (20.8) |
T3b | 59 (16.1) | 6 (10) | 53 (17.3) |
T4 | 9 (2.4) | 1 (1.7) | 8 (2.6) |
Nerve sparing | n (%) | n (%) | n (%) |
125 | 24 (19.2) | 101 (80.8) |